GlobalData on MSN

Roche sizes up first BTK inhibitor approval on Phase III MS victory

If fenebrutinib got the FDA go-ahead, it would become the first BTK inhibitor to gain approval in both RMS and PPMS.

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK in…

The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib ...
650 CKOM

Volunteer firefighter joins call for public inquiry into wildfire response

Harley Vliegenthart wants a public inquiry into the government’s response to the wildfire season, saying it’s the public that ...

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas BioP ...
Scientific Research Publishing

Intelligent Agents in Cybersecurity: Deep Learning to Analyze User Behavior Applying ()

The research aim is to develop an intelligent agent for cybersecurity systems capable of detecting abnormal user behavior ...

Fifth Third Bancorp (FITB) Presents at The BancAnalysts Association of Boston Conference Transcript

The BancAnalysts Association of Boston Conference November 7, 2025 9:00 AM ESTCompany ParticipantsBryan Preston - Executive ...
Tax Guru

Analysis of Notifications and Circulars for Week ending 2nd November 2025

CPC gets power to rectify AO orders; ITR due date extended; GST registration simplified, and returns barred after 3 years; Customs imposes 30% duty on yellow peas; SEBI amends Mutual Fund, REIT, and ...